Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties
Authors:
- Pedro Mm MesquitaPMPedro Mm Mesquita
- Priya SrinivasanPSPriya Srinivasan
- Todd J JohnsonTJTodd J Johnson
- Rachna RastogiRRRachna Rastogi
- Tammy Evans-StrickfadenTETammy Evans-Strickfaden
- Michael S KayMKMichael S Kay
- Karen W BuckheitKBKaren W Buckheit
- Robert W BuckheitRBRobert W Buckheit
- James M SmithJSJames M Smith
- Patrick F KiserPKPatrick F Kiser
- Betsy C HeroldBHBetsy C Herold
Open Access
- 24 October 2013
- journal article
- Published by Springer Nature in Retrovirology
- Vol. 10 (1) , 113
Abstract
The limited success of recent HIV topical pre-exposure prophylaxis clinical trials highlights the need for more predictive models of drug efficacy that better simulate what may happen during sexual exposure. To address this gap, we developed complementary in vitro models to evaluate the ability of drugs to retain anti-HIV activity if cells were washed with seminal plasma (simulating what may happen following exposure to ejaculate), and to protect drug-naive T cells (representing newly recruited immune cells) co-cultured with explants that had been pretreated with drug. We focused on tenofovir disoproxil fumarate (TDF), the non-nucleoside reverse transcriptase inhibitors dapivirine (DPV) and IQP-0528, and the entry inhibitors maraviroc (MVC) and the D-peptide chol-PIE-12 trimer (PIE12). Studies were extended to macaques and the ability of cervical biopsies obtained from animals treated with an intravaginal ring formulation of IQP-0528 to protect ex vivo co-cultured T cells was determined. The antiviral activity of cervicovaginal lavage samples against a primary Clade C isolate was also measured and correlated with drug levels.Keywords
This publication has 32 references indexed in Scilit:
- Adherence Support Approaches in Biomedical HIV Prevention Trials: Experiences, Insights and Future Directions from Four Multisite Prevention TrialsAIDS and Behavior, 2013
- Preexposure Prophylaxis for HIV Infection among African WomenNew England Journal of Medicine, 2012
- Maraviroc and Other HIV-1 Entry Inhibitors Exhibit a Class-Specific Redistribution Effect That Results in Increased Extracellular Viral LoadAntimicrobial Agents and Chemotherapy, 2012
- Safe and Sustained Vaginal Delivery of Pyrimidinedione HIV-1 Inhibitors from Polyurethane Intravaginal RingsAntimicrobial Agents and Chemotherapy, 2012
- Microbicides: Topical Prevention against HIVCold Spring Harbor Perspectives in Medicine, 2011
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with MenNew England Journal of Medicine, 2010
- Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infectionJournal of Antimicrobial Chemotherapy, 2010
- PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trialThe Lancet, 2010
- Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in WomenScience, 2010
- Candidate Microbicide PPCM Blocks Human Immunodeficiency Virus Type 1 Infection in Cell and Tissue Cultures and Prevents Genital Herpes in a Murine ModelJournal of Virology, 2008